RASL11A

Across TCGA pan-cancer cohorts, RASL11A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RASL11A data layer compared with 25 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RASL11A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RASL11A expression acts as an unfavorable survival marker.

LIHC and UCEC are the cancer types where RASL11A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.046	0.553	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RASL11A–LIHC (DFS)

Open the LIHC breakdown →